167 related articles for article (PubMed ID: 30696657)
41. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
42. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer.
Shi J; Lu P; Shen W; He R; Yang MW; Fang Y; Sun YW; Niu N; Xue J
Cancer Lett; 2019 Jul; 453():158-169. PubMed ID: 30954649
[TBL] [Abstract][Full Text] [Related]
43. Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion.
Karnevi E; Andersson R; Rosendahl AH
Immunol Cell Biol; 2014 Jul; 92(6):543-52. PubMed ID: 24662521
[TBL] [Abstract][Full Text] [Related]
44. Characterization of Mouse Models of Early Pancreatic Lesions Induced by Alcohol and Chronic Pancreatitis.
Xu S; Chheda C; Ouhaddi Y; Benhaddou H; Bourhim M; Grippo PJ; Principe DR; Mascariñas E; DeCant B; Tsukamoto H; Pandol SJ; Edderkaoui M
Pancreas; 2015 Aug; 44(6):882-7. PubMed ID: 26166469
[TBL] [Abstract][Full Text] [Related]
45. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
46. Expansion of Th
Harada T; Miki H; Cui Q; Oda A; Amachi R; Teramachi J; Bat-Erdene A; Sogabe K; Iwasa M; Fujii S; Nakamura S; Kagawa K; Yoshida S; Endo I; Aihara K; Ozaki S; Matsumoto T; Abe M
Leukemia; 2017 Jan; 31(1):258-262. PubMed ID: 27698446
[No Abstract] [Full Text] [Related]
47. Obesity and Fatty Pancreatic Infiltration Are Risk Factors for Pancreatic Precancerous Lesions (PanIN).
Rebours V; Gaujoux S; d'Assignies G; Sauvanet A; Ruszniewski P; Lévy P; Paradis V; Bedossa P; Couvelard A
Clin Cancer Res; 2015 Aug; 21(15):3522-8. PubMed ID: 25700304
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.
Gay F; Mina R; Troia R; Bringhen S
Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1517-27. PubMed ID: 23961770
[TBL] [Abstract][Full Text] [Related]
49. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions.
Neesse A; Hahnenkamp A; Griesmann H; Buchholz M; Hahn SA; Maghnouj A; Fendrich V; Ring J; Sipos B; Tuveson DA; Bremer C; Gress TM; Michl P
Gut; 2013 Jul; 62(7):1034-43. PubMed ID: 22677720
[TBL] [Abstract][Full Text] [Related]
50. Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer.
Albazaz R; Verbeke CS; Rahman SH; McMahon MJ
Pancreatology; 2005; 5(4-5):361-9. PubMed ID: 15980665
[TBL] [Abstract][Full Text] [Related]
51. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
52. Targeting tumor-associated macrophages to combat pancreatic cancer.
Cui R; Yue W; Lattime EC; Stein MN; Xu Q; Tan XL
Oncotarget; 2016 Aug; 7(31):50735-50754. PubMed ID: 27191744
[TBL] [Abstract][Full Text] [Related]
53. Tumor-associated macrophages in oral premalignant lesions coexpress CD163 and STAT1 in a Th1-dominated microenvironment.
Mori K; Haraguchi S; Hiori M; Shimada J; Ohmori Y
BMC Cancer; 2015 Aug; 15():573. PubMed ID: 26242181
[TBL] [Abstract][Full Text] [Related]
54. Low doses of gamma irradiation potentially modifies immunosuppressive tumor microenvironment by retuning tumor-associated macrophages: lesson from insulinoma.
Prakash H; Klug F; Nadella V; Mazumdar V; Schmitz-Winnenthal H; Umansky L
Carcinogenesis; 2016 Mar; 37(3):301-313. PubMed ID: 26785731
[TBL] [Abstract][Full Text] [Related]
55. Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer.
Das M; Shen L; Liu Q; Goodwin TJ; Huang L
Mol Ther; 2019 Mar; 27(3):507-517. PubMed ID: 30545600
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease.
Lopez-Millan B; Diaz de la Guardia R; Roca-Ho H; García-Herrero CM; Lavoie JR; Rosu-Myles M; Gonzalez-Rey E; O'Valle F; Criado G; Delgado M; Menendez P
Exp Mol Med; 2017 Feb; 49(2):e290. PubMed ID: 28154372
[TBL] [Abstract][Full Text] [Related]
57. Macrophages in pancreatic cancer: An immunometabolic perspective.
Yang J; Li Y; Sun Z; Zhan H
Cancer Lett; 2021 Feb; 498():188-200. PubMed ID: 33122097
[TBL] [Abstract][Full Text] [Related]
58. Pomalidomide-induced changes in the pancreatic tumor microenvironment and potential for therapy.
Storz P
Oncoscience; 2019 Jul; 6(7-8):351-353. PubMed ID: 31608297
[No Abstract] [Full Text] [Related]
59. Inflammatory and alternatively activated macrophages independently induce metaplasia but cooperatively drive pancreatic precancerous lesion growth.
Liou GY; Fleming Martinez AK; Döppler HR; Bastea LI; Storz P
iScience; 2023 Jun; 26(6):106820. PubMed ID: 37250781
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
